temazepam

temazepam
Name	Temazepam
Drug class	Benzodiazepine hypnotic
Routes of administration	Oral
Legal status	Varies by country

temazepam is a short- to intermediate-acting benzodiazepine hypnotic indicated primarily for short-term management of insomnia. It modulates gamma-aminobutyric acid A receptors and is prescribed in multiple countries with differing legal controls, manufacturing standards, and clinical guidelines. Clinical use, pharmacology, adverse effect profiles, dependence potential, contraindications, and sociocultural impacts have been discussed in regulatory, medical, and forensic literature.

Medical uses

Temazepam is used for short-term treatment of insomnia characterized by sleep-onset difficulty or sleep-maintenance problems in adults. Clinical practice guidelines from organizations in United Kingdom, United States, Canada, Australia, and New Zealand typically recommend limiting use to two to four weeks, with exceptions noted by agencies such as the National Institute for Health and Care Excellence and the Food and Drug Administration. In hospital settings, temazepam may be used for procedural sedation adjuncts in institutions like Mayo Clinic and Johns Hopkins Hospital under specialist supervision, and is discussed in formularies of university hospitals such as Massachusetts General Hospital and Charité – Universitätsmedizin Berlin. Off-label use has been described in psychiatric services at centers including Maudsley Hospital and Bellevue Hospital for acute insomnia in mood disorders, though professional bodies like the American Psychiatric Association caution about limited evidence.

Pharmacology

Temazepam is a benzodiazepine that acts as a positive allosteric modulator at the benzodiazepine binding site of the GABAA receptor, enhancing inhibitory neurotransmission similarly to agents discussed in textbooks used at institutions such as Harvard Medical School, Stanford University School of Medicine, University of Oxford, and Yale School of Medicine. Its pharmacokinetic profile—oral absorption, hepatic metabolism involving conjugation pathways reviewed by researchers at Karolinska Institutet and Imperial College London, and renal excretion—parallels benzodiazepines profiled in monographs from World Health Organization collaborating centers. The onset and half-life attributes are compared in pharmacology resources at UCL Medical School and University of Toronto Faculty of Medicine to other sedative-hypnotics like agents studied at McGill University and Columbia University Irving Medical Center.

Drug–drug interactions with cytochrome-modulating agents are considered in formularies at Cleveland Clinic and Royal Brisbane and Women's Hospital; interactions with opioids—a topic of guidance by Centers for Disease Control and Prevention and European Medicines Agency—increase risks of respiratory depression. Therapeutic monitoring and considerations for special populations appear in guidance from World Health Organization, European Agency for the Evaluation of Medicinal Products, and national agencies such as Health Canada.

Adverse effects

Common adverse effects reported in clinical trials and pharmacovigilance databases maintained by organizations like FDA Adverse Event Reporting System, European Medicines Agency Pharmacovigilance, and agencies in Japan include daytime drowsiness, dizziness, and headache—symptoms also cataloged in hospital adverse event committees at Guy's and St Thomas' NHS Foundation Trust and Karolinska University Hospital. Cognitive and psychomotor impairment affecting activities overseen by institutions such as Transport for London and Federal Aviation Administration have prompted regulatory advisories. Rare but serious events, including complex sleep-related behaviors, have been investigated by academic centers like University of California, San Francisco and University of Sydney and reported to bodies such as Medicines and Healthcare products Regulatory Agency.

Dependence and withdrawal

Prolonged use of temazepam has risk of physical dependence and withdrawal syndromes, documented in longitudinal studies at centers including King's College London, University of Edinburgh, Vanderbilt University Medical Center, and University of Pennsylvania. Withdrawal manifestations—insomnia rebound, anxiety, tremor, and, in severe cases, seizures—are addressed in detoxification protocols at specialist units like Priory Group clinics and addiction services affiliated with Beth Israel Deaconess Medical Center. Tapering regimens and substitution strategies are discussed in consensus statements from bodies such as the Royal College of Psychiatrists and the American Society of Addiction Medicine.

Contraindications and precautions

Contraindications include acute narrow-angle conditions evaluated in ophthalmology departments at Moorfields Eye Hospital and Bascom Palmer Eye Institute, myasthenia gravis cases managed at neurology centers like National Hospital for Neurology and Neurosurgery, and severe respiratory insufficiency as encountered at Royal Brompton Hospital and John Radcliffe Hospital. Caution is advised in elderly patients as per geriatric medicine guidelines from British Geriatrics Society and American Geriatrics Society due to fall risk and cognitive effects; perioperative and obstetric considerations have been discussed in protocols from Royal College of Obstetricians and Gynaecologists and American College of Obstetricians and Gynecologists.

Legal status and regulation

Temazepam scheduling and control vary: many jurisdictions classify it under controlled substances frameworks similar to listings by United Nations Office on Drugs and Crime, national agencies such as the Drug Enforcement Administration in the United States, the Home Office and Medicines and Healthcare products Regulatory Agency in the United Kingdom, and the Therapeutic Goods Administration in Australia. Regulatory actions, including packaging restrictions and prescription monitoring, have been enacted following reports to agencies like Health Canada and the European Commission. International treaties and national statutes influence manufacturing, distribution, and forensic analysis conducted by laboratories at institutions like FBI Laboratory and Metropolitan Police Forensic Services.

Society and culture

Temazepam has featured in public health discussions, media reporting, and forensic casework in countries including Ireland, Scotland, Wales, Germany, and France. Cultural and legal responses echo cases and policy debates involving other psychoactive drugs noted in inquiries at UK Parliament and commissions such as Royal Commission-style bodies. Harm reduction, prescription monitoring programs, and educational campaigns reference multidisciplinary collaborations among organizations like World Health Organization, European Monitoring Centre for Drugs and Drug Addiction, National Health Service, Centers for Disease Control and Prevention, and local public health departments in major cities including London, New York City, Toronto, and Sydney.

Category:Benzodiazepines